Atreca, Inc. (BCEL)
OTCMKTS: BCEL · Delayed Price · USD
0.0901
-0.0061 (-6.33%)
May 3, 2024, 11:34 AM EDT - Market open
Atreca Revenue
Atreca had revenue of $263.00K in the twelve months ending September 30, 2023. Revenue in the quarter ending September 30, 2023 was $80.00K. In the year 2022, Atreca had annual revenue of $770.00K, a decrease of -9.52%.
Revenue (ttm)
$263.00K
Revenue Growth
-9.52%
P/S Ratio
14.50
Revenue / Employee
$2,922
Employees
90
Market Cap
3.57M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 770.00K | -81.00K | -9.52% |
Dec 31, 2021 | 851.00K | -502.00K | -37.10% |
Dec 31, 2020 | 1.35M | -781.00K | -36.60% |
Dec 31, 2019 | 2.13M | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
BCEL News
- 4 months ago - BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc. - Business Wire
- 4 months ago - Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome - GlobeNewsWire
- 4 months ago - Immunome to Acquire Antibody-Related Assets and Materials from Atreca - Business Wire
- 6 months ago - Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives - GlobeNewsWire
- 8 months ago - Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross - GlobeNewsWire
- 9 months ago - Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring - GlobeNewsWire
- 11 months ago - Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting - GlobeNewsWire
- 1 year ago - Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments - GlobeNewsWire